Avid Bioservices Inc (CDMO)

[dumbster]

perzackly when does perception become reality?


With pphm, I believe you can see it happening before your eyes.

I noted--with displeasure--the phrase in write-up of "3-takeaways from CC" that stated "...there's not much in the pipeline". That seems to be perception shared by many outsiders looking in, and of many posters on this board. I take exception and umbrage to this.

If our betabodies patents aren't a major expansion of our pipeline, then perhaps I'm under a misconception.

As I recall, betabodies not only have very broad application in human cancer treatment, but also in veterinary and very important agricultural usages. Perhaps even one might be justified in saying broader than those of bavi.

Now, I'm cognizant that in our current financial straits, we have not the funds necessary to launch any clinical research that might advance betabodies beyond the conceptual stage. So what COULD we do to move this forward? Would it be totally out of order to provide the research arms of a major veterinary and a major agricultural firm with sufficient betabodies materials, along with our suggestions for primary opportunities for joint ventures, and let them do some preclinical work for us in THEIR specialties?

Wouldn't that constitute "collaborations" that would move betabodies forward at very low cost to us, with perhaps mutually profitable results?

Every release pphm puts out refers to "lead candidate bavituximab"...why can't that be re-phrased in some manner to include reference to betabodies? How is anybody else 'sposed to know we've got more in the pipeline than just bavi if WE don't tell them? In the past, didn't someone refer to betabodies as second-generation bavi, or was it next-generation? Aren't we missing an opportunity in this?

In short, I believe the company should begin to eliminate the impression that we're a one-trick pony. If we can enhance our footprint, we can enhance our odds for greater success.